Welcome to our dedicated page for ICON news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON stock.
ICON plc reports developments for a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology companies. Its news commonly covers operating and financial results, clinical trial management activity, net business wins, revenue guidance, and service areas such as patient recruitment, data analytics, laboratory services and regulatory consulting.
Company updates also address partnerships that connect clinical trial technology with research-site systems, expansion of the Accellacare Site Network in therapeutic areas including oncology, and governance or accounting-control matters tied to revenue recognition and financial reporting.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ICON plc (NASDAQ: ICLR) reported its Q1 2023 financial results with net business wins of $2,415 million and a book-to-bill ratio of 1.22. Revenues reached $1,978.6 million, up 4.0% year-over-year. The adjusted EBITDA stood at $399.1 million, 20.2% of revenue, reflecting a 17.2% increase. GAAP net income was $116.7 million, or $1.41 per share. The company reaffirmed its full-year 2023 revenue guidance in the range of $7,940 - $8,340 million and adjusted EPS guidance of $12.40 - $13.05, indicating a year-on-year growth of 5.5% to 11.1%. Cash flow from operations amounted to $175.5 million, with a net debt of $4.2 billion and a debt-to-adjusted EBITDA ratio of 2.8x.